Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy

Patients with PR but the maximum diameter of tumor \> 3cm or SD or PD can receive surgery directly.

After surgery, adjuvant Chemoradiotherapy or radiotherapy will be given for patients with high-risk factors.

Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.